Sotyktu to treat plaque psoriasis
Drug Name: Sotyktu Active Ingredient: deucravacitinib Indications: To treat moderate-to-severe plaque psoriasis Approval Date: 9/9/2022 Company: Bristol-Myers Squibb Company Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf